Skip to main content
. 2019 Feb 1;10(4):330–336. doi: 10.1136/flgastro-2018-101024

Table 3.

Multivariate analysis of factors associated with infliximab discontinuation due to SLR or SAE

Factor OR CI for OR P value
TDM never tested 8.0 3.8 to 17.0 <0.01
Pre-TDM era 0.65 0.3 to 1.4 0.28
Previous exposure to biologic 4.4 1.8 to 10.7 <0.01
Total duration of follow-up 1.01 0.99 to 1.02 0.07

SAE, serious adverse event; SLR, secondary loss of response; TDM, therapeutic drug monitoring.